Biological therapies in thrombocytopenia and primary antiphospholipid syndrome: where are we now? in Expert opinion on biological therapy / Expert Opin Biol Ther. 2025 Mar 28. doi: 10.1080/14712598.2025.2484844.

2025
ASL Città di Torino

Tipo pubblicazione

Editorial

Autori/Collaboratori (9)Vedi tutti...

Radin M
Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, and SCDU Nephrology and Dialysis, S. Giovanni Bosco Hospital, Turin, Italy.
Barinotti A
Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, and SCDU Nephrology and Dialysis, S. Giovanni Bosco Hospital, Turin, Italy.
Galarza D
Department of Rheumatology, Hospital del Mar Barcelona, Barcelona, Spain.

et alii...

Accesso banca dati bibliografica

Accedi alla scheda bibliografica del documento in PUBMED

Se sei accreditato in BVS-P effettua prima l'accesso per utilizzare i nostri servizi.

PMID : 40151064

DOI : 10.1080/14712598.2025.2484844

Keywords

APS; Belimumab; antiphospholipid; thrombocytopenia;